AbbVie (NYSE:ABBV) Upgraded at Canaccord Genuity Group

Canaccord Genuity Group upgraded shares of AbbVie (NYSE:ABBV) to a strong-buy rating in a research note released on Monday morning,Zacks.com reports.

Several other equities research analysts have also commented on the company. UBS Group decreased their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Evercore decreased their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Cantor Fitzgerald decreased their price target on AbbVie from $250.00 to $240.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 8th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research note on Wednesday, January 28th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $200.43 on Monday. The business’s 50 day simple moving average is $217.87 and its 200-day simple moving average is $222.77. The firm has a market capitalization of $354.39 billion, a price-to-earnings ratio of 84.93, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. AbbVie has a 12 month low of $174.40 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts anticipate that AbbVie will post 14.22 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.5%. AbbVie’s payout ratio is 293.22%.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Red Door Wealth Management LLC raised its holdings in AbbVie by 1.7% in the 1st quarter. Red Door Wealth Management LLC now owns 47,908 shares of the company’s stock valued at $10,419,000 after acquiring an additional 798 shares during the last quarter. Aspire Private Capital LLC grew its stake in shares of AbbVie by 13.0% during the 1st quarter. Aspire Private Capital LLC now owns 9,130 shares of the company’s stock valued at $1,986,000 after buying an additional 1,047 shares during the period. Matrix Asset Advisors Inc. NY grew its stake in shares of AbbVie by 2.3% during the 1st quarter. Matrix Asset Advisors Inc. NY now owns 39,175 shares of the company’s stock valued at $8,520,000 after buying an additional 890 shares during the period. Patriot Financial Group Insurance Agency LLC grew its stake in shares of AbbVie by 105.5% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 30,644 shares of the company’s stock valued at $6,665,000 after buying an additional 15,733 shares during the period. Finally, Lam Group Inc. purchased a new stake in shares of AbbVie during the 1st quarter valued at $64,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $1.4 billion, 185‑acre manufacturing campus in Durham, NC — its largest single‑site capital investment — intended to support production of immunology, neuroscience and oncology medicines and create ~734 permanent jobs and 2,000+ construction roles. AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
• Positive Sentiment: Major news outlets (Reuters) confirmed the $1.4B campus — highlighting this as AbbVie’s biggest investment in a single site, which supports a long‑term manufacturing footprint and onshoring narrative. AbbVie to build $1.4 billion manufacturing campus in North Carolina
• Positive Sentiment: Stocks initially reacted positively to the site announcement (coverage noted intraday gains), reflecting investor interest in tangible, capital‑intensive commitments that strengthen production capacity. AbbVie (ABBV) Stock Surges After Unveiling $1.4B North Carolina Manufacturing Hub
• Positive Sentiment: Canaccord initiated coverage with a “strong‑buy”/Buy rating and a $262 target, calling AbbVie a core holding and reinforcing a constructive analyst view on the company’s franchise growth trajectory. Canaccord Calls AbbVie a Core Holding With a $262 Target
• Neutral Sentiment: AbbVie’s broader investor visibility and corporate initiatives (e.g., sponsoring BioLabs in Toronto) continue to draw attention but are background items with uncertain immediate price impact. AbbVie Sponsors New BioLabs Facility in Toronto
• Neutral Sentiment: Analyst and retail‑investor pieces (Zacks, Yahoo summaries) are raising attention ahead of earnings, keeping the stock in focus; these items may amplify volatility but don’t change fundamentals by themselves. AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Zacks published cautionary pieces stating AbbVie “doesn’t possess the right combination” to deliver a likely earnings beat in the upcoming report — a near‑term catalyst that can pressure the stock if results disappoint. AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
• Negative Sentiment: Market writeups explained the intraday decline as profit‑taking after recent gains and as investors weigh near‑term earnings risk despite the positive capital investment headlines. Here’s Why AbbVie (ABBV) Fell More Than Broader Market

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.